Abstract
Cardiovascular complications are among the main reasons for the high morbidity and mortality in patients with type 2 diabetes, making the management of cardiovascular complications an integral component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of newly developed anti-diabetic agents with properties of mitigating cardiovascular risk in patients with type 2 diabetes. Evidence from clinical trials has suggested that the SGLT2 inhibitors empagliflozin and canagliflozin are capable of reducing the overall risk of cardiovascular events and mortality in type 2 diabetic patients. In this mini-review, we will briefly discuss the various cardiovascular benefits of SGLT2 inhibitors, and the underlying mechanisms involved.
Keywords: SGLT2, GLP-1, DPP-4, type 2 diabetes, cardiovascular, clinical.
Current Drug Targets
Title:Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Volume: 19 Issue: 9
Author(s): Dylan Y. Ren and Yingmei Zhang*
Affiliation:
- School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071,United States
Keywords: SGLT2, GLP-1, DPP-4, type 2 diabetes, cardiovascular, clinical.
Abstract: Cardiovascular complications are among the main reasons for the high morbidity and mortality in patients with type 2 diabetes, making the management of cardiovascular complications an integral component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of newly developed anti-diabetic agents with properties of mitigating cardiovascular risk in patients with type 2 diabetes. Evidence from clinical trials has suggested that the SGLT2 inhibitors empagliflozin and canagliflozin are capable of reducing the overall risk of cardiovascular events and mortality in type 2 diabetic patients. In this mini-review, we will briefly discuss the various cardiovascular benefits of SGLT2 inhibitors, and the underlying mechanisms involved.
Export Options
About this article
Cite this article as:
Ren Y. Dylan and Zhang Yingmei *, Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon, Current Drug Targets 2018; 19 (9) . https://dx.doi.org/10.2174/1389450119666180531102227
DOI https://dx.doi.org/10.2174/1389450119666180531102227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oral Glucose-lowering Drugs and Cardiovascular Outcomes: From the Negative RECORD and ACCORD to Neutral TECOS and Promising EMPA-REG
Current Vascular Pharmacology Cardiovascular Complications of Sleep Disorders: A Better Night’s Sleep for a Healthier Heart / From Bench to Bedside
Current Vascular Pharmacology Coronary Microvascular and Cardiac Dysfunction Due to Homocysteine Pathometabolism; A Complex Therapeutic Design
Current Pharmaceutical Design Systemic Redox Biomarkers in Neurodegenerative Diseases
Current Drug Metabolism The G Protein β3 Subunit Gene (GNB3) 825T Allele - a Thrifty Genotype
Current Genomics Recent Advances in the Development of Pharmaceutical Agents for Metabolic Disorders: A Computational Perspective
Current Medicinal Chemistry Hyperfibrinogenemia is Significantly Associated with an Increased Risk of In-hospital Mortality in Acute Ischemic Stroke Patients
Current Neurovascular Research Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA Editorial (Thematic Issue: Antiplatelet Treatment in Cardiovascular Disease: New Insights)
Current Pharmaceutical Design The Protective Effect of Metformin against Oxandrolone-Induced Infertility in Male Rats
Current Pharmaceutical Design Metabolic Control Analysis and its Applications
Current Bioinformatics Protection by Nigella Sativa [Black Seed] against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Polycystic Ovary Syndrome and Infertility: From Molecular Perspective
Current Women`s Health Reviews Insulin Resistance, Oxidative Stress and Cardiovascular Complications: Role of Sirtuins
Current Pharmaceutical Design Endothelial Nitric Oxide Synthase Gene Therapy for Erectile Dysfunction
Current Pharmaceutical Design Angiotensin-(1-7) Improves Islet Function in a Rat Model of Streptozotocin- Induced Diabetes Mellitus by Up-Regulating the Expression of Pdx1/Glut2
Endocrine, Metabolic & Immune Disorders - Drug Targets Hitting the Jackpot Twice: Identifying and Patenting Gene Tests Related to Muscle Lipid Accumulation for Meat Quality in Animals and Type 2 Diabetes/Obesity in Humans
Recent Patents on DNA & Gene Sequences Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
Current Pharmaceutical Design